Informace o publikaci

gamma H2AX/53BP1 foci as a potential pre-treatment marker of HNSCC tumors radiosensitivity - preliminary methodological study and discussion

Logo poskytovatele
Autoři

FALK M. HORÁKOVÁ Zuzana SVOBODOVÁ Markéta MASAŘÍK Michal KOPECNA O. GUMULEC Jaromír RAUDENSKÁ Martina DEPES D. BACIKOVA A. FALKOVA I. BINKOVÁ Hana

Rok publikování 2017
Druh Článek v odborném periodiku
Časopis / Zdroj The European Physical Journal D
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.1140/epjd/e2017-80073-2
Obor Fyziologie
Klíčová slova HNSCC tumor
Popis In order to improve patients' post-treatment quality of life, a shift from surgery to non-surgical (chemo) radio-treatment is recognized in head and neck oncology. However, about half of HNSCC tumors are resistant to irradiation and an efficient marker of individual tumor radiosensitivity is still missing. We analyzed whether various parameters of DNA double strand break (DSB) repair determined in vitro can predict, prior to clinical treatment initiation, the radiosensitivity of tumors. We compared formation and decrease of gamma H2AX/53BP1 foci in 48 h after irradiating tumor cell primocultures with 2 Gy of gamma-rays. To better understand complex tumor behavior, three different cell type primocultures - CD90(-), CD90(+), and a mixed culture of these cells - were isolated from 1 clinically radioresistant, 2 radiosensitive, and 4 undetermined HPV-HNSCC tumors and followed separately. While DSB repair was delayed and the number of persisting DSBs increased in the radiosensitive tumors, the results for the radioresistant tumor were similar to cultured normal human skin fibroblasts. Hence, DSB repair kinetics/efficiency may correlate with clinical response to radiotherapy for a subset of HNSCC tumors but the size (and therefore practical relevance) of this subset remains to be determined. The same is true for contribution of different cell type primocultures to tumor radioresistance.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info